Enveric Biosciences Stock Analysis
ENVB Stock | USD 0.34 0.01 2.86% |
Enveric Biosciences is undervalued with Real Value of 2.39 and Target Price of 8.5. The main objective of Enveric Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Enveric Biosciences is worth, separate from its market price. There are two main types of Enveric Biosciences' stock analysis: fundamental analysis and technical analysis.
The Enveric Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Enveric Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Enveric |
Enveric Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enveric Biosciences recorded a loss per share of 2.42. The entity last dividend was issued on the 23rd of April 2008. The firm had 1:50 split on the 15th of July 2022. Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Enveric Biosciences, Inc. is headquartered in Naples, Florida. Enveric Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people. To learn more about Enveric Biosciences call Joseph Tucker at 239-302-1707 or check out https://www.enveric.com.Enveric Biosciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Enveric Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Enveric Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Enveric Biosciences generated a negative expected return over the last 90 days | |
Enveric Biosciences has some characteristics of a very speculative penny stock | |
Enveric Biosciences has high historical volatility and very poor performance | |
Enveric Biosciences has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (17.29 M) with profit before overhead, payroll, taxes, and interest of 8.15 M. | |
Enveric Biosciences currently holds about 18.01 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Enveric Biosciences has a very weak financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Enveric Biosciences Stock Price Up 1.1 percent Whats Next |
Enveric Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enveric Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of April 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
1st of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Enveric Largest EPS Surprises
Earnings surprises can significantly impact Enveric Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.52 | -0.2395 | 0.2805 | 53 | ||
2024-08-12 | 2024-06-30 | -0.55 | -0.25 | 0.3 | 54 | ||
2024-05-15 | 2024-03-31 | -0.77 | -0.42 | 0.35 | 45 |
Enveric Stock Institutional Investors
Shares | Bank Of America Corp | 2024-06-30 | 164 | Nelson, Van Denburg & Campbell Wealth Management Group, Llc | 2024-09-30 | 50.0 | Wells Fargo & Co | 2024-06-30 | 16.0 | Mather Group, Inc. | 2024-06-30 | 8.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Org Partners Llc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Advisorshares Investments, Llc | 2024-06-30 | 317 K | Geode Capital Management, Llc | 2024-06-30 | 44.7 K |
Enveric Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.48 M.Enveric Profitablity
Last Reported | Projected for Next Year | ||
Return On Capital Employed | (8.41) | (7.99) | |
Return On Equity | (0.01) | (0.01) |
Management Efficiency
Enveric Biosciences has return on total asset (ROA) of (0.805) % which means that it has lost $0.805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.061) %, meaning that it created substantial loss on money invested by shareholders. Enveric Biosciences' management efficiency ratios could be used to measure how well Enveric Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.0044. The current year's Return On Capital Employed is expected to grow to -7.99. At present, Enveric Biosciences' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.1 M, whereas Total Assets are forecasted to decline to about 4.1 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.91 | 0.86 | |
Tangible Book Value Per Share | 0.81 | 0.85 | |
Enterprise Value Over EBITDA | (0.03) | (0.03) | |
Price Book Value Ratio | 1.43 | 1.36 | |
Enterprise Value Multiple | (0.03) | (0.03) | |
Price Fair Value | 1.43 | 1.36 | |
Enterprise Value | 518.8 K | 492.9 K |
The leadership approach at Enveric Biosciences' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.469 | Return On Assets (0.81) | Return On Equity (2.06) |
Technical Drivers
As of the 21st of November, Enveric Biosciences shows the Mean Deviation of 3.27, standard deviation of 4.74, and Variance of 22.49. Enveric Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enveric Biosciences Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Enveric Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Enveric Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Enveric Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enveric Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enveric Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enveric Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dickey Robert Iv over a month ago Insider Trading | ||
Coveney Kevin Michael over a month ago Acquisition by Coveney Kevin Michael of 100000 shares of Enveric Biosciences subject to Rule 16b-3 | ||
Sikaria Lokesh over a month ago Disposition of 14119 shares by Sikaria Lokesh of Enveric Biosciences at 0.3003 subject to Rule 16b-3 | ||
Lokesh Sikaria Trust Dated 12/14/2012 over two months ago Disposition of 14119 shares by Lokesh Sikaria Trust Dated 12142012 of Enveric Biosciences at 0.3003 subject to Rule 16b-3 | ||
Sikaria Lokesh over three months ago Disposition of 1500 shares by Sikaria Lokesh of Enveric Biosciences at 0.3011 subject to Rule 16b-3 | ||
Dewitt Sheila over three months ago Insider Trading | ||
Sikaria Lokesh over six months ago Disposition of 1515 shares by Sikaria Lokesh of Enveric Biosciences at 0.3006 subject to Rule 16b-3 | ||
Joseph Tucker over a year ago Acquisition by Joseph Tucker of 44000 shares of Enveric Biosciences subject to Rule 16b-3 |
Enveric Biosciences Outstanding Bonds
Enveric Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enveric Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enveric bonds can be classified according to their maturity, which is the date when Enveric Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Enveric Biosciences Predictive Daily Indicators
Enveric Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enveric Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Enveric Biosciences Forecast Models
Enveric Biosciences' time-series forecasting models are one of many Enveric Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Enveric Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Enveric Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Enveric Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Enveric shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Enveric Biosciences. By using and applying Enveric Stock analysis, traders can create a robust methodology for identifying Enveric entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.13) | (0.12) | |
Operating Profit Margin | (0.14) | (0.15) | |
Net Loss | (0.14) | (0.13) | |
Gross Profit Margin | 0.23 | 0.22 |
Current Enveric Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Enveric analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Enveric analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
8.5 | Buy | 1 | Odds |
Most Enveric analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Enveric stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Enveric Biosciences, talking to its executives and customers, or listening to Enveric conference calls.
Enveric Stock Analysis Indicators
Enveric Biosciences stock analysis indicators help investors evaluate how Enveric Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Enveric Biosciences shares will generate the highest return on investment. By understating and applying Enveric Biosciences stock analysis, traders can identify Enveric Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 17.7 M | |
Common Stock Shares Outstanding | 2.2 M | |
Total Stockholder Equity | 2 M | |
Tax Provision | -1.5 M | |
Property Plant And Equipment Net | 507.4 K | |
Cash And Short Term Investments | 2.3 M | |
Cash | 2.3 M | |
Accounts Payable | 1.2 M | |
Net Debt | -2.3 M | |
50 Day M A | 0.4642 | |
Total Current Liabilities | 2.3 M | |
Other Operating Expenses | 16.4 M | |
Non Current Assets Total | 718.3 K | |
Forward Price Earnings | 23.0947 | |
Non Currrent Assets Other | 567.6 K | |
Stock Based Compensation | 2.2 M |
Complementary Tools for Enveric Stock analysis
When running Enveric Biosciences' price analysis, check to measure Enveric Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enveric Biosciences is operating at the current time. Most of Enveric Biosciences' value examination focuses on studying past and present price action to predict the probability of Enveric Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enveric Biosciences' price. Additionally, you may evaluate how the addition of Enveric Biosciences to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Managers Screen money managers from public funds and ETFs managed around the world |